TPO-RAs have an obvious potential to affect the course of the disease [47,48,49], but until further studies are done, we suggest keeping the first-line treatment of ITP as indicated in IWG guidelines [10] and in our protocol [27]—corticosteroids ± IVIG. Here, TPO is linked to autoimmune thrombocytopenic purpura.